DBV Technologies S.A.

NasdaqCM:DBVT Stock Report

Market Cap: US$54.4m

DBV Technologies Management

Management criteria checks 3/4

DBV Technologies' CEO is Daniel Tassé, appointed in Nov 2018, has a tenure of 5.67 years. total yearly compensation is $2.40M, comprised of 25% salary and 75% bonuses, including company stock and options. directly owns 0.018% of the company’s shares, worth $9.63K. The average tenure of the management team and the board of directors is 5.2 years and 5.7 years respectively.

Key information

Daniel Tassé

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage25.0%
CEO tenure6yrs
CEO ownership0.02%
Management average tenure5.2yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

FDA puts partial clinical hold on a DBT Technologies peanut allergy patch phase 3 trial

Sep 21

DBV Technologies GAAP EPS of -$0.35 misses by $0.03, revenue of $1.53M beats by $0.29M

Aug 01

DBV Technologies: Good Data, Plenty Of Cash And Regulatory Uncertainty

Jul 07

DBV Technologies reports change in U.S. reporting status, cuts headcount

Jan 07

DBV Technologies CSO Hugh Sampson to step down from role

Nov 24

DBV Technologies shares rockets 85% as EMA approves Viaskin Peanut application

Nov 02

CEO Compensation Analysis

How has Daniel Tassé's remuneration changed compared to DBV Technologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$102m

Jun 30 2024n/an/a

-US$88m

Mar 31 2024n/an/a

-US$80m

Dec 31 2023US$2mUS$600k

-US$73m

Sep 30 2023n/an/a

-US$101m

Jun 30 2023n/an/a

-US$101m

Mar 31 2023n/an/a

-US$100m

Dec 31 2022US$3mUS$600k

-US$96m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$2mUS$600k

-US$98m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$131m

Mar 31 2021n/an/a

-US$148m

Dec 31 2020US$2mUS$600k

-US$160m

Sep 30 2020n/an/a

-US$161m

Jun 30 2020n/an/a

-US$171m

Mar 31 2020n/an/a

-US$169m

Dec 31 2019US$3mUS$600k

-US$172m

Sep 30 2019n/an/a

-US$176m

Jun 30 2019n/an/a

-US$198m

Mar 31 2019n/an/a

-US$191m

Dec 31 2018US$5mUS$55k

-US$190m

Compensation vs Market: Daniel's total compensation ($USD2.40M) is above average for companies of similar size in the US market ($USD650.80K).

Compensation vs Earnings: Daniel's compensation has been consistent with company performance over the past year.

CEO

Daniel Tassé (64 yo)

6yrs

Tenure

US$2,404,486

Compensation

Mr. Daniel Tasse had been an Independent Non-Executive Director of Indivior PLC since August 2014 until May 6, 2021 and Senior Independent Director since September 30, 2016 until May 6, 2021. Mr. Tasse ser...

Leadership Team

NamePositionTenureCompensationOwnership
Daniel Tassé
CEO & Director6yrsUS$2.40m0.018%
$ 9.6k
Virginie Simone Jeanine Boucinha
CFO & Principal Accounting Officerless than a yearUS$509.31kno data
Pharis Mohideen
Chief Medical Officer5.3yrsUS$1.28m0.024%
$ 13.1k
Kevin Malobisky
Chief Operations Officerless than a yearno datano data
Katie Matthews
Investor Relations Officerno datano datano data
Michele Robertson
Chief Legal Officer3.8yrsno datano data
Caroline Daniere
Chief Human Resources Officer & Chief of Staff5.2yrsno datano data
Wence Agbotounou
Chief Clinical Trial Officer & Senior VP8.5yrsno datano data
Edward Jordan
Senior Vice President of Commercial Operations North America8.8yrsno datano data
Alan Kerr
Senior VP & Head of Global Regulatory Affairs5.8yrsno datano data
Pascal Wotling
Chief External Manufacturing & Supply Chain Officerless than a yearno datano data
Robert Pietrusko
Chief Regulatory Officerless than a yearno datano data

5.2yrs

Average Tenure

57.5yo

Average Age

Experienced Management: DBVT's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Daniel Tassé
CEO & Director5.7yrsUS$2.40m0.018%
$ 9.6k
Timothy Morris
Independent Director3.7yrsUS$113.54k0.012%
$ 6.8k
Michel de Rosen
Independent Chairman of the Board6.5yrsUS$10.81k0.024%
$ 13.3k
Michael Goller
Director9.1yrsUS$113.54k0%
$ 0
Daniel Soland
Independent Director9.7yrsUS$113.54k0.026%
$ 14.1k
Mailys Ferrere
Director8.4yrsno datano data
Hugh Sampson
Scientific Adviser to the CEO & Chairman of Scientific Advisory Board3.9yrsno datano data
Paul-Henri Lambert
Member of the Scientific Advisory Boardno datano datano data
Emma Guttman-Yassky
Member of Scientific Advisory Board5.5yrsno datano data
Julie O'Neill
Director7.4yrsUS$113.54k0%
$ 0
Jean-François Nicolas
Member of Scientific Advisory Board5.5yrsno datano data
Jim Krueger
Member of Scientific Advisory Board5.5yrsno datano data

5.7yrs

Average Tenure

64yo

Average Age

Experienced Board: DBVT's board of directors are considered experienced (5.7 years average tenure).